University of Toronto, Department of Psychiatry, 825 Coxwell Avenue, Toronto, ON M4C 3E7, Canada.
Expert Opin Pharmacother. 2012 Aug;13(11):1575-85. doi: 10.1517/14656566.2011.608351. Epub 2011 Sep 20.
Personality disorders are among the most persistent and challenging disorders to treat within psychiatry. There is emerging evidence that some personality disorders, particularly borderline personality disorder and, to a lesser extent, schizotypal personality disorder, may benefit from treatment with atypical antipsychotics as well as mood stabilizers. This review examines the evidence for atypical antipsychotics for personality disorders and discusses strengths and limitations of this approach.
Searches of Medline and PsycInfo yielded 57 articles related to use of atypical antipsychotics for treatment of personality disorders. Most were relatively small randomized, controlled trials examining atypical antipsychotics for borderline personality disorder; however, the search also yielded two Cochrane reviews examining pharmacotherapy for borderline personality disorder and antisocial personality disorder as well as three other meta-analyses.
There is some evidence that atypical antipsychotics are effective for treating symptom domains in personality disorders, in particular psychotic-like symptoms, impulsivity, aggression and anger. There is no evidence that they improve overall illness severity. Given the high rate of comorbidity between personality disorders and axis I disorders, atypical antipsychotics are best used when these symptom domains are prominent and there is a comorbid axis I condition for which an atypical antipsychotic is indicated.
人格障碍是精神病学中最持久和最具挑战性的治疗障碍之一。越来越多的证据表明,一些人格障碍,特别是边缘型人格障碍,在一定程度上也包括分裂型人格障碍,可能受益于非典型抗精神病药物和心境稳定剂的治疗。本文综述了非典型抗精神病药物治疗人格障碍的证据,并讨论了这种方法的优缺点。
对 Medline 和 PsycInfo 的检索共获得了 57 篇与非典型抗精神病药物治疗人格障碍相关的文章。大多数是相对较小的随机对照试验,研究了非典型抗精神病药物治疗边缘型人格障碍;然而,检索还产生了两项关于边缘型人格障碍和反社会型人格障碍药物治疗的 Cochrane 综述,以及另外三项荟萃分析。
有一些证据表明,非典型抗精神病药物在治疗人格障碍的症状领域,特别是类精神病症状、冲动、攻击和愤怒方面是有效的。没有证据表明它们能改善整体疾病严重程度。鉴于人格障碍与轴 I 障碍之间的高共病率,当这些症状领域突出且存在轴 I 疾病需要非典型抗精神病药物治疗时,非典型抗精神病药物最适合使用。